Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Clinical Data

23andMe study explains variable results with obesity drugs

 April 9, 2026

Pharmaphorum

Gene variants could explain why some people lose more weight than others with GLP-1 drugs, and why some are more prone to side effects.

Clinical DataMetabolic & GLP-1Read full story

Post navigation

EverSea Medicines to acquire Hasten Biopharmaceuticals →
← The FTC Blows Up Express Scripts’ PBM Model–and Launches the Net Pricing Drug Channel (rerun)

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com